Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
- Conditions
- Corona Virus InfectionSars-CoV2
- Interventions
- Registration Number
- NCT04356495
- Lead Sponsor
- University Hospital, Bordeaux
- Brief Summary
In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.
- Detailed Description
COVERAGE France is Multicenter, randomized, controlled clinical trial with for each drug :
* A safety study pilot phase.
* An efficacy study phase. The data collected during the pilot phase, combined with new external data that emerged during the period, will be used to position treatments for the efficacy phase.
* Pilot phase will evaluate the tolerance of experimental treatments for drugs given for the first time ("first in home-based care") in ambulatory individuals with COVID-19 with aggravating risk factors.
* Efficacy Phase: To estimate the effectiveness of experimental ambulatory treatments, compared to vitamin supplementation, in reducing the risk of hospitalization, oxygen therapy indication or death in ambulatory individuals with COVID-19 with aggravating risk factors.
The trial is a national platform with the vocation to open as many centers as possible, subject to criteria set by the Scientific Advisory Board.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 412
-
Clinical picture suggestive of COVID-19 dated 7 days or less.
-
Positivity of a test proving an acute SARS-CoV-2 infection, according to current recommendations.
-
Absence of criteria for hospitalization or oxygen therapy according to current recommendations.
-
Age :
-
greater than or equal to 60 years of age without any risk factor
-
or between 50 and 59 years of age and the presence of at least one of the following risk factors :
- Arterial hypertension under treatment (all stages)
- Obesity (BMI ≥30 kg/m2)
- Diabetes under treatment (all types)
- Ischemic heart disease (all stages)
- Heart failure (all stages)
- Stroke History
- Chronic Obstructive Pulmonary Disease (all stages)
- Stage 3 chronic renal failure (30 ≤ Estimated GFR < 60 mL/min/1.73 m²)
- Malignancies (solid tumours or blood malignancies) that are progressive or were diagnosed less than 5 years ago.
- Immunodeficiency
-
-
of therapeutic origin (solid organ transplant or hematopoietic stem cell transplant, cancer chemotherapy, immunosuppressive therapy, corticosteroids > 15 mg/d of prednisone equivalent taken for at least 2 months);
-
HIV infection with CD4<200/mm3.
-
Valid, ambulatory person, fully able to understand the issues of the trial
-
Beneficiary of a Social Security scheme
-
Signed informed consent
- Asymptomatic person
- Inability to make a decision to participate (dementia, person under legal protection, curatorship or guardianship)
- Ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description interferon β-1b interferon β-1b Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days Vitamins Vitamins Patients in this arm will receive a vitamin supplement ("AZINC forme et vitalité®") during 10 days Ciclesonide Ciclesonide Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days Telmisartan Telmisartan Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
- Primary Outcome Measures
Name Time Method Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse event From inclusion (day0) to day 14 Efficacy phase: hospitalization From inclusion (day0) to day 14 Proportion of participants who had an indication for hospitalization
Efficacy phase: oxygen therapy From inclusion (day0) to day 14 Proportion of participants who had an indication for oxygen therapy
Efficacy phase: Death From inclusion (day0) to day 14 Proportion of participants with an occurrence of death
- Secondary Outcome Measures
Name Time Method Proportion of hospitalizations, overall and by cause, in each group From inclusion (day0) to day 28 Proportion of participants with negative SARS-CoV-2 RT-PCR day 7 Haematological markers evolution from inclusion (day 0) to day 7 Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR
Proportion of intensive care hospitalizations, overall and by cause, in each group From inclusion (day0) to day 28 Death and causes of death From inclusion (day0) to day 28 Proportion of deaths, overall and by cause, in each group
Inflammatory markers evolution from inclusion (day 0) to day 7 Evolution of Inflammatory markers in each group : PCT, CRP
Adverse events from inclusion (day 0) to day 28 Number and proportion of grade 1,2,3,4 adverse events in each group
Adverse reactions from inclusion (day 0) to day 28 Number and proportion of grade 1,2,3,4 adverse events in each group
Acceptability of the treatment from inclusion (day 0) to day 10 Acceptability of the treatment by participant will be assessed with an interview
Oxygen saturation worsening from inclusion (day 0) to day 28 Proportion of participants who experienced a worsening of oxygen saturation
Antibiotic consumption from inclusion (day 0) to day 28 Proportion of participants who received at least one day of antibiotic therapy
protocol follow-up from inclusion (day 0) to day 10 Proportion of participants who completed the prescribed protocol treatment
Trial Locations
- Locations (7)
Bordeaux university Hospital
🇫🇷Bordeaux, France
CNGE
🇫🇷Paris, France
CHU de Montpellier
🇫🇷Montpellier, France
CHU de Toulouse
🇫🇷Toulouse, France
CHU de Dijon-Bourgogne
🇫🇷Dijon, France
CHRU de Nancy
🇫🇷Nancy, France
Groupe hospitalier Paris Saint Joseph
🇫🇷Paris, France